Novartis raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped ...

Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given ...

Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its ...

Novartis' drug segment is poised for steady cash flows driven by new pipeline products and existing drugs. Novartis' strategy to focus largely in areas of unmet medical need should strengthen the ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

The drug is now on the market in several EU countries, however, its price (around $42,500 in the US, which translates to just ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis NOVN-1.67%decrease ... boosted by revenue from its blockbuster drugs. The Swiss pharmaceutical giant said Tuesday that it now expects its core operating profit—one of its preferred ...